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Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease that is 
characterized by accumulation of amyloid beta forming senile plaques and the deposition 
of microtubule-associated tau proteins into neurofibrillary tangles. It is primarily a 
disease of synaptic dysfunction and the loss of synapses can be correlated with cognitive 
decline. Oxidative stress also has been hypothesized to play an increasingly important 
role in pathogenesis of late onset AD. Using brain samples from participants in the 
Baltimore Longitudinal Study of Aging (BLSA) we developed and optimized a protein 
extraction protocol to investigate key proteins involved in oxidative pathways and the 
temporal relationship of synaptic dysfunction to onset of cognitive dysfunction. Using 
age matched samples from the BLSA who are cognitively normal, have mild cognitive 
impairment and those with dementia we investigated the role of TOMM40, COV-IV, 
synaptophysin and PSD95. Samples from the superior and middle temporal gyrus 
(SMTG) and middle frontal gyrus (MFG) were homogenized and soluble extracellular, 
cellular and insoluble fractions were extracted. Using semi-quantitative Western blotting 
the concentration of these proteins were measured and correlated with the onset of 
clinical symptoms of Alzheimer’s disease.   
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Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease and 
the most common cause of dementia. In Alzheimer’s disease, neuronal damage 
eventually affects parts of the brain that enable a person to carry out basic bodily 
functions such as walking, swallowing etc. More than 35 million people worldwide have 
AD - a deterioration of memory and other cognitive domains that leads to death within 3 
– 9 years after diagnosis. Dementia is also caused by other diseases and is characterized 
by a decline in memory, problem-solving, language and other cognitive skills that affects 
a person’s ability to perform everyday activities [1]. 
 
Alzheimer’s disease symptoms vary among individuals. The most common initial 
symptom is a gradually worsening ability to remember new information. The first 
neurons to malfunction and die are usually neurons in brain regions involved in forming 
new memories [2]. The common symptoms of AD are as follows:  
 Memory loss that disrupts daily life. 
 Difficulty completing familiar tasks at home or work 
 Trouble understanding visual images and spatial relationships. 
 Misplacing things and losing the ability to retrace steps. 
 Decreased or poor judgment. 
 Challenges in planning or solving problems. 
 Confusion with time or place. 
 Withdrawal from work or social activities. 
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 Changes in mood and personality, including apathy and depression. 
 
 
Figure 1: Normal brain vs an Alzheimer’s disease brain showing shrinkage of 
hippocampus and cerebral cortex; and enlarged ventricles  
(Source: Courtesy of ADEAR - Alzheimer’s disease Education and Referral Center, a 
service of the National Institute on Aging) 
 
The pace at which symptoms advance from mild to moderate to severe varies from 
person to person. The principal risk factor for AD is age. The incidence of the disease 
doubles every 5 years after 65 years of age. As the disease progresses, cognitive and 
functional abilities decline. People need help with basic activities of daily living. They 
lose their ability to communicate; fail to recognize loved ones and become reliant on 




PROTEIN ABNORMALITIES IN ALZHEIMER'S DISEASE: 
For over 100 years, scientists have recognized a strong correlation between the clinical 
signs of late-life dementia and the presence in brain of abnormal protein deposits. The 
brains of people with advanced AD show dramatic shrinkage from cell loss and 
widespread debris from dead and dying neurons. Accumulation of misfolded proteins in 
the ageing brain results in oxidative and inflammatory damage, which in turn leads to 
energy failure and synaptic dysfunction In AD, these deposits contain aggregated peptide 
fragments of various proteins, including the amyloid precursor protein (APP), the 
microtubule-associated tau protein and others. The accumulation of beta-amyloid forming 
senile plaques outside neurons and the deposition of microtubule-associated tau proteins 
forming neurofibrillary tangles inside neurons are two of several brain changes believed 
to contribute to the development of AD. The accumulation of amyloid beta interferes 
with the neuronal communication at synapses and contributes to cell death. Tau 
neurofibrillary tangles block the transport of nutrients and other essential molecules 
inside neurons. Subcortical structures are lost including 75% or more of the cells of the 
basal nucleus of Meynert, the dorsal raphe and the locus coeruleus [4].  
 
The important pathological features of Alzheimer's disease are cerebral plaques laden 
with β-amyloid peptide (Aβ) and neurofibrillary tangles in medial temporal-lobe 
structures [5].  Aβ peptides are natural products of metabolism consisting of 36 to 43 
amino acids. Beta amyloid peptides originate from proteolysis of the amyloid precursor 
protein by the sequential enzymatic actions of beta-site amyloid precursor protein–
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cleaving enzyme 1 (BACE-1), a β-secretase, a γ-secretase, a protein complex with 
presenilin 1 at its catalytic core. An imbalance between production, clearance and 
aggregation of peptides causes Aβ to accumulate, and this excess may be the initiating 
factor in Alzheimer's disease. This idea called the “amyloid hypothesis,” is based on 
studies of genetic forms of Alzheimer's disease, including Down's syndrome and 
evidence that Aβ42 is toxic to cells [1].  
 
Figure 2: Changes in tau protein leading to disintegration of microtubules in brain 
cells 
(Source: Courtesy of ADEAR - Alzheimer’s disease Education and Referral Center, a 
service of the National Institute on Aging) 
 
Neurofibrillary tangles are seen in Alzheimer's disease and other neurodegenerative 
disorders called tauopathies. Tau promotes assembly and stability of microtubules and 
vesicle transport. The number of neurofibrillary tangles is a pathologic marker of the 
severity of Alzheimer's disease.  An abnormally hyperphosphorylated and aggregated 
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form of tau is known to be a component of tangles. Hyperphosphorylated tau is insoluble, 
lacks affinity for microtubules and self-associates into helical filament structures. [1] 
MILD COGNITIVE IMPAIRMENT: 
Mild Cognitive Impairment (MCI) is an intermediate stage between the expected 
cognitive decline of normal aging and the more pronounced decline of dementia. It 
involves problems with memory, language, thinking, and judgment that are greater than 
typical age-related changes. These changes associated with MCI aren’t severe enough to 
interfere with day-to-day life and ordinary activities.  Unlike dementia, where cognitive 
abilities gradually decline, the memory deficits in MCI may remain stable for years. 
However it is seen that some individuals with MCI will develop Alzheimer’s disease. The 
ability to learn and retain new information is called episodic memory. An impairment in 
this kind of memory is most commonly seen in MCI patients who subsequently progress 
to a diagnosis of AD. 
 MCI that primarily affects memory is known as amnestic MCI wherein a person may 
start to forget important information that he or she would previously have recalled 
easily. 
 MCI that affects thinking skills other than memory is known as non-amnestic MCI. 
Thinking skills are affected including the ability to make sound decisions and judging 
the time or sequence of steps needed to complete a complex task [6].  
 
Studies have shown that there are a variety of episodic memory tests that are useful for 
identifying those MCI patients who have a high likelihood of progressing to AD 
dementia within a few years whereby it is possible to determine retention over a delay. It 
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is important to examine domains in addition to memory such as executive functions 
(reasoning, problem-solving), language (fluency, speech, and comprehension), 
visuospatial skills, and attentional control. Many validated clinical neuropsychological 
measures are available to assess these cognitive domains, including the Trail Making Test 
(executive function), the Boston Naming Test, letter and category fluency (language), 
figure copying (spatial skills) and digit span forward (attention) [7].  
 
 
Figure 3: Progression of Alzheimer’s disease 
(Source: Pihlajamäki, Maija, and Reisa A. Sperling. "fMRI: use in early Alzheimer's 
disease and in clinical trials." (2008): 409-421) 
 
There are genetic influences on the development of late onset AD. The presence of an ε4 
allele in the APOE gene is the only gene broadly accepted as increasing risk for late-
onset AD, while the ε2 allele decreases risk. Evidence suggests that an individual who 
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meets the clinical, cognitive and etiologic criteria for MCI due to AD, and is also ApoE-4 
positive, is more likely to progress to AD within a few years than an individual without 




Figure 4: Synaptic Dysfunction in Alzheimer’s disease 
(Source: Querfurth Henry W, LaFerla Frank M. Review Article: Alzheimer's disease. N 
Engl J Med 2010; 362:329-344 DOI: 10.1056/NEJMra0909142) 
 
Alzheimer's disease may be primarily a disorder of synaptic failure. Synaptic loss is the 
best pathological correlate of cognitive impairment in subjects with AD. The relation 
between synaptic activity and Aβ in AD pathogenesis is an area that is widely discussed. 
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Chronic synaptic activity could be detrimental since addition of extracellular amyloid 
beta alters synapses and impairs synaptic plasticity. Hippocampal synapses begin to 
decline in patients with mild cognitive impairment in whom remaining synaptic profiles 
show compensatory increases in size [9].  In mild Alzheimer's disease, there is a 
reduction of about 25% in the presynaptic vesicle protein synaptophysin. With advancing 
disease, synapses are disproportionately lost relative to neurons, and this loss is the best 
correlate with dementia. Aging itself causes synaptic loss which particularly affects the 




Translocase of outer mitochondrial membrane 40 homolog (yeast), also known 
as TOMM40, is a protein which in humans is encoded by the TOMM40 gene. The protein 
encoded by this gene is localized in the outer membrane of the mitochondria. It is the 
channel-forming subunit of the translocase of the mitochondrial outer membrane (TOM) 
complex that is essential for import of protein precursors into 
mitochondria. TOMM40 codes for a protein that is embedded into outer membranes of 
mitochondria and is required for the movement of proteins into mitochondria. More 
precisely, TOMM40 is the channel-forming subunit of a translocase of the mitochondrial 




Figure 5: Role of TOMM40 in Alzheimer’s disease 
(Source: Osherovich, L. SciBX 2(24); doi:10.1038/scibx.2009.962) 
 
The TOMM40 gene, which encodes a mitochondrial protein, lies on chromosome 19 
adjacent to the gene encoding apolipoprotein E (APOE), a well-known AD risk factor. 
DNA sequencing of 340 individuals revealed two forms of a noncoding region within 
the TOMM40 gene. 
(I) The most common form contains a short sequence repeat and correlates with an 
average age of AD onset of 78 years in carriers of the AD-neutral APOE allele E3 [a], 
whereas an alternative, longer repeat sequence correlates with average age of AD onset of 
70 years in E3 carriers (n=105, p<0.03) [b]. The long form is also present in nearly all 
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carriers of APOEallele E4 [c], which was previously shown by Roses to correlate with 
early AD onset. 
 (II) APOE functions outside of the neuron, physically separated from an abnormal form 
of TOMM40. Abnormal TOMM40 could lead to mitochondrial dysfunction, apoptosis 
and eventually AD in an APOE-independent manner. 
(III) Alternatively, intracellular APOE protein and TOMM40 protein could interact at the 
mitochondrial surface to disrupt mitochondrial metabolism, leading to apoptosis and AD. 
(IV) The length variation in the TOMM40 gene could influence the expression of the 
adjacent APOE gene. The short form of TOMM40 could lead to strong transcription 
of APOE and thus normal E3 protein levels that protect against disease [a]. However, the 
long form of TOMM40 could dampen expression of E3 [b] or E4 [c], leading to 
inadequate APOE protein levels and subsequently to AD. 
In humans, certain alleles of this gene have been statistically associated with an increased 
risk of developing late-onset Alzheimer's disease. One study has found that TOMM40 
risk alleles appears twice as often in people with Alzheimer's disease than those without 
it. Because TOMM40 is located on chromosome 19, and is closely adjacent to APOE, 
another gene known to be associated with Alzheimer's, another study has suggested that 
the statistically significant correlation of TOMM40 with Alzheimer's is due to linkage 






Synaptophysin, also known as the major synaptic vesicle protein p38, is a protein that in 
humans is encoded by the SYP gene. The encoded protein has 313 amino acids with a 
predicted molecular weight of 38 kDa [17]. It is present in neuroendocrine cells and in 
virtually all neurons in the brain and spinal cord that participate in synaptic transmission. 
It acts as a marker for neuroendocrine tumors, and its ubiquity at the synapse has led to 
the use of synaptophysin immunostaining for quantification of synapses [18].  
 
Figure 6: Possible role of synpatophysin in neurodegenerative disorders 
 
(Source:Trends Biochem Sci. 2015 July; 40(7): 385–396. Published online 2015 April 




Synaptophysin was the first synaptic vesicle protein to be cloned and characterized and is 
known to belong to a family of proteins with 4 transmembrane domains that includes 
synaptogyrin and synaptoporin. Syp is the most abundant SV protein by mass, accounting 
for ~10 % of total vesicle protein. Because syp is exclusively localized to SVs, it is 




Figure 7: Inflammatory stress in Alzheimer’s disease 
 
(Source: Aisen, Paul S. The potential of anti-inflammatory drugs for the treatment of 
Alzheimer's disease. The Lancet Neurology , Volume 1 , Issue 5 , 279 – 284) 
 
Cytochrome c oxidase (COX) is a heterooligomeric enzyme consisting of 13 subunits 
localized to the inner mitochondrial membrane. It is the terminal enzyme complex in the 
respiratory chain, catalyzing the reduction of molecular oxygen to water coupled to the 
translocation of protons across the mitochondrial inner membrane to drive ATP synthesis. 
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The 3 largest subunits forming the catalytic core are encoded by mitochondrial DNA 
while the other smaller subunits, including COX IV, are nuclear-encoded [20]. 
Deficiency in COX activity has been correlated with a number of human diseases. This 
protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the 
terminal oxidase in mitochondrial electron transport [21].  
4. PSD95 
 
PSD-95 (Post Synaptic Density Protein 95) also known as SAP-90 (synapse-associated 
protein 90) is a protein that in humans is encoded by the DLG4 (discs large homolog 
4) gene. PSD-95 is a member of the membrane-associated guanylate kinase (MAGUK) 
family. PSD-95 a membrane associated guanylate kinase (MAGUK) scaffolding protein 
located in neural postsynaptic densities. Like all MAGUK-family proteins, its basic 
structure includes three PDZ domains, an SH3 domain, and a guanylate kinase-like 
domain (GK) connected by disordered linker regions. It is almost exclusively located in 
the post synaptic density of neurons and is involved in anchoring synaptic proteins. Its 
direct and indirect binding partners include neuroligin, NMDA receptors, AMPA 
receptors, and potassium channels. It plays an important role in synaptic plasticity and the 
stabilization of synaptic changes during long-term potentiation.  
It is required for synaptic plasticity associated with NMDA receptor signaling. Its 
overexpression or depletion changes the ratio of excitatory to inhibitory synapses in 
hippocampal neurons. High levels in postsynaptic density of neurons in the forebrain. 
Also in presynaptic region of inhibitory synapses formed by cerebellar basket cells on 
axon hillocks of Purkinje cells [22, 23].  
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Figure 8: Role of PSD95 in Alzheimer’s disease 
 
(Source: Lars M. Ittner & Jürgen Götz. Amyloid-β and tau — a toxic pas de deux in 




N-methyl-D-aspartate (NMDA) receptor-evoked excitotoxicity contributes to region-








MATERIALS AND METHODS 
 
In order to develop and optimize an extraction protocol for quantitative proteomic studies 
to investigate key proteins involved in oxidative pathways in Alzheimer’s disease, we 
used mouse brain tissue followed by human brain tissue samples. Human tissue samples 
were obtained from the Baltimore Longitudinal Study of Aging (BLSA) and were 
categorized by the Consortium to Establish a Registry for Alzheimer’s disease (CERAD) 
- established in 1986 by a grant from the National Institute on Aging (NIA), to 
standardize procedures for the evaluation and diagnosis of patients with Alzheimer’s 
disease (AD). Patients and non-demented control subjects were recruited from 24 NIA-
sponsored Alzheimer’s disease Research Centers and other university programs in the 
US.  
 
1. CHEMICALS AND REAGENTS 
 
a. RIPA Buffer 
 
RIPA buffer derives its name from the original application for which it was developed: 
the radio-immunoprecipitation assay. RIPA cell lysis reagent is highly effective for 
protein extraction from a variety of cell types because it contains three non-ionic and 
ionic detergents. It is a sensitive assay using radiolabeled antigens to detect 
specific antibodies in serum. RIPA Buffer does not contain protease or phosphatase 
inhibitors. It enables efficient cell lysis and protein solubilization while avoiding protein 
degradation and interference with the proteins′ immunoreactivity and biological activity. 
It also results in low background in immunoprecipitation and molecular pull-down 
assays. It is suitable for small scale affinity pull-down assays such as 
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immunoprecipitation and for western blotting. It minimizes non-specific protein binding 
interactions to ensure low background. This buffer is more denaturing than NP-40 
or Triton X-100 lysis buffer because it contains the ionic detergents SDS and sodium 
deoxycholate as active constituents and is particularly useful for disruption of nuclear 
membranes in the preparation of nuclear extracts. The antigens are allowed to react with 
the serum and then precipitated using a special reagent such as protein A sepharose 
beads. The bound radiolabeled immunoprecipitate is then commonly analyzed by gel 
electrophoresis [25, 26].  
RIPA buffer's rapid and efficient cell lysis and solubilization of a wide range of proteins, 
including cytoplasmic, membrane and nuclear proteins, makes it a standard for Western 
blotting.  When protein quantitation is desired, RIPA buffer is the lysis buffer of choice 
due to its compatibility with the BCA Protein Assay, although it can denature kinases and 
can disrupt protein-protein interactions in immunoprecipitation/pull down assays 
Composition: 50 mM Tris HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS.  
b. Urea Buffer 
 
Urea buffer is another versatile and efficient cell and tissue lysing buffer whose typical 
composition includes: TRIS base 40 mM, Urea 7 M, Thiourea 2 M, NP-40 or CHAPS 
4%, DTT 10 mM. Urea is used at concentrations ranging from 5 to 9 M, often with 
thiourea at concentrations up to 2 M. The additive thiourea can dramatically enhance the 
solubility of a wide range of proteins – nuclear, membrane, cytosolic, and including even 
tubulin that is highly prone to aggregation, in urea buffer.  Urea inactivates proteases that 
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degrade cellular proteins. Therefore, there is little need to add protease inhibitors. 
However, urea and thiourea can hydrolyze to cyanate and thiocyanate, respectively, 
which can modify amino groups on proteins, (e.g. carbamylation of proteins by 
isocyanate), and this hydrolysis is promoted by heat [27].  
 
2. BRAIN SAMPLES 
 
a. Mouse brain tissue – 25 to 50 mg of mouse brain tissue was used with RIPA or 
urea buffer followed by sonication and/or homogenization.   
b. Human brain tissue –We categorized our samples from the superior and middle 
temporal gyrus (SMTG) and middle frontal gyrus (MFG) into three groups: 
Three postmortem groups were studied: controls with normal and stable cognition; 
cognitively intact subjects with senile plaque densities diagnostic for possible AD (p-AD) 
and neurofibrillary changes characteristic of early AD; and individuals with definite AD 
and neurofibrillary changes typical of incipient to severe AD  
Normal: At any age, persons may potentially be free of objective or subjective symptoms 
of cognition and functional decline and also free of associated behavioral and mood 
changes.  
MCI: An intermediate stage between the expected cognitive decline of normal aging and 
the more pronounced decline of dementia. Memory deficits in MCI may remain stable for 
years. 
AD: Using standardized diagnostic criteria and assessment instruments, CERAD subjects 
were examined at entry and annually thereafter, to observe the natural progression of AD. 
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Autopsy examination of the brain was included, to obtain neuropathologic confirmation 
of the clinical diagnosis. Brain tissue was homogenized in liquid nitrogen and the brain 
powder was stored at −80 °C.  
 
3. PROTEIN EXTRACTION 
 
Homogenization: 
In cell biology or molecular biology research, homogenization is a process whereby a 
biological sample is brought to a state such that all fractions of the sample are equal in 
composition, i.e. a homogenized sample is mixed so well that removing some of the 
sample does not alter the overall molecular make-up of the sample remaining, and is 
identical to the fraction removed. Homogenization in biology is often followed by or 
combined with, cell lysis and/or molecular extraction [28].  
Purification of protein from animal and human tissues using TissueLyser LT: 
 
Placed 2 ml microcentrifuge tubes containing 1 stainless steel bead (5 mm mean 
diameter) on dry ice for at least 15 minutes. Kept the insert of the TissueLyser LT 
Adapter at room temperature. Transferred up to 30 mg fresh or frozen tissue to the pre-
cooled tubes and incubated for another 15 minutes on dry ice. Placed the tubes into the 
insert of the TissueLyser LT Adapter and incubated at room temperature for 2 minutes to 
avoid freezing of lysis buffer. Incubating for longer than 2 minutes results in potential 
protein degradation. Immediately added the appropriate volume of lysis buffer to each 
tube. Placed the insert with sample tubes into the base of the TissueLyser LT Adaptor, 
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which is attached to the TissueLyser LT. Operated the TissueLyser LT for 2-5 minutes at 
50 Hz until no tissue debris was visible.  
Sonication:  
Sonication is a process in which sound waves are used to agitate particles in solution.  
The sound waves used in sonication are usually ultrasound waves with frequencies above 
above 20 kHz and as frequency increases the strength of the agitation increases. In 
solution, the particles vibrate because as they experience cycles of pressure, microscopic 
vacuum bubbles form and then collapse into solution, a process called cavitation. These 
vibrations can disrupt molecular interactions, break clumps of particles apart, and lead to 
mixing.  In the case of dissolved gas, these vibrations can allow the gas bubbles to come 
together and more easily leave the solution. Indirect sonication is most effective for very 
small samples because foaming and sample loss are eliminated. 
 
Protein extraction from tissues using Bioruptor: 
Used the Bioruptor Standard to sonicate the brain tissue, adding ice-cold lysis buffer. 
Proceeded to sonicate with the following settings:  
Power: H position (High)  
Sonication cycle: 30 sec ON/30 sec OFF  
Total sonication time: 5-10 cycles  
Temperature: 4°C  
 
Vortexed samples after every 5 cycles and visually inspected them to find that they were 
in soluton and viscosity had reduced. Transferred the supernatant to a new tube and 
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centrifuged samples at 14,000 rpm for 15 min at 4°C to remove any remaining insoluble 
material. Stored protein extracts at -80°C. 
 
4. PROTEIN QUANTIFICATION 
 
Lowry Assay: 
Under alkaline conditions the divalent copper ion forms a complex with peptide bonds in 
which it is reduced to a monovalent ion. Monovalent copper ion and the radical groups of 
tyrosine, tryptophan, and cysteine react with Folin reagent to produce an unstable product 
that becomes reduced to molybdenum/tungsten blue.  
The Bio-Rad DC Protein Assay is a colorimetric assay for protein concentration. The 
reaction reaches 90% of its maximum color development within 15 minutes thereby 
saving valuable time and the color changes not more than 5% in 1 hour or 10% in 2 hours 
after the addition of reagents.  Proteins effect a reduction of the Folin reagent by loss of 
1, 2, or 3 oxygen atoms, thereby producing one or more of several possible reduced 
species which have a characteristic blue color with maximum absorbance at 750 nm and 
minimum absorbance at 405 nm. 
1. Preparation of Working Reagent: Added 20 µl of reagent S to each ml of reagent 
A needed for the run.  
2. Preparation of a standard curve:  A standard curve was prepared each time the 
assay was performed. 
a. Prepared 6 dilutions of the protein standard from 0.1 mg/mL to 1 mg/mL protein.  
b. Sample Calculation: 1430 µg in 1000 µL 
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   100 µg = 100*1000 = 69.93 µL of Standard       (100µg = 0.1mg) 
                     1430 
         
 
c. Made it up to 1000 µL with the buffer ( Triton X-100 buffer) 
Sr. No. Conc(mg/mL) Vol.of stock (µL) Vol. of Triton-X-
100 buffer (µL) 
1 0.1 69.93 930.07 
2 0.2 139.86 860.14 
3 0.4 279.72 720.28 
4 0.6 419.58 580.42 
5 0.8 559.44 440.56 
6 1 699.30 300.70 
        
         Table 1: Sample calculation table to perform the Lowry Assay 
 
Sample Calculation: 69.93 µL of standard + 930.07 µL of Buffer (For a 
concentration of 100µg) 
 
d. Pipetted 100µL of the above into clean, dry test tubes. 
e. Added 500 µL of working reagent (A+S prepared before) into each test tube. 
Vortex. 
f. Added 4.0 mL of reagent B into each test tube and vortexed immediately. 
g. After 15 minutes, absorbances were read at 750 nm using the Smart Spec Plus.  
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Bradford Assay:  
The Bradford protein assay is a colorimetric protein assay originally described by Marion 
Bradford which uses a disulfonated tripheynlmethane compound called Coomassie 
Brilliant Blue G-250 (CBB G-250). Under acidic conditions the protein binds to mostly 
basic amino acids such as arginine, lysine and other amino acids including histidine. 
Under these conditions, dye-amino acid binding results in a shift dye pKa of the dye 
causing the color to change from green/brown tint to blue. The protein-bound dye is 
measured at 595 nm. The more protein, the more intense the blue color. Amino acid 
composition as well as post-translational modification of proteins can lead to variation of 
dye intensity. The amount of absorbance of the bound dye at 595 nm is linearly related to 




Antibody Host Clonality Immunogen Molecular 
Weight 
Isotype 
TOMM40 Rabbit Polyclonal Recombinant 
protein of human 
TOMM40 
38 kDa IgG 
Synaptophysin Mouse Monoclonal Electrophoretically 
purified 
synaptophysin 
38 kDa IgG1 
COX-IV Rabbit Polyclonal  15 kDa IgG 
PSD95 Rabbit Polyclonal Synthetic peptide 
conjugated to 
KLH derived from 
within residues 50-
150 of Mouse 
PSD95 
95 kDa IgG 
 





































Table 3: Characteristics of peptides used in experiments 
 
7. WESTERN BLOTS  
 
The term "blotting" refers to the transfer of biological samples from a gel to a membrane 
and their subsequent detection on the surface of the membrane. Western blotting, also 
called immunoblotting because an antibody is used to specifically detect its antigen, was 
introduced by Towbin, et al. in 1979 and is now a routine technique for protein analysis. 
The specificity of the antibody-antigen interaction enables a target protein to be identified 
in the midst of a complex protein mixture. Western blotting can produce qualitative and 
semi-quantitative data about that protein. 
The most sensitive detection methods use a chemiluminescent substrate that, when 
combined with the enzyme, produces light as a byproduct. The light output can be 
captured using film, a CCD camera or a phosphorimager that is designed for 
chemiluminescent detection. Alternatively, fluorescently tagged antibodies can be used, 
which are directly detected with the aid of a fluorescence imaging system. Whatever 
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system is used, the intensity of the signal should correlate with the abundance of the 
antigen on the membrane. 
DIRECT METHOD: 
 
Figure 9: Principle of using the direct method in Western Blots 
 
(Source: ThermoFisher Scientific: Western Blotting Handbook) 
 
This method is quick since only one antibody is used. There is no concern for cross-
reactivity of a secondary antibody. Labeling may reduce immunoreactivity of primary 
antibody. The labeled primary antibodies are expensive and there is low flexibility in 











Figure 10: Principle of using the indirect method in Western Blots 
 
(Source: ThermoFisher Scientific: Western Blotting Handbook) 
 
Here the secondary antibody can amplify signal and a variety of labeled secondary 
antibodies are available. One secondary may be used with many primary antibodies 
Labeling does not affect primary antibody immunoreactivity and changing secondary 









 Prepared samples in lysis buffer to concentration of lowest sample. Added 20 uL 
of mixed 2x Laemmli and beta mercaptonal sample buffer (prepare by adding 50 
uL beta mercaptonal to 950 uL laemmli buffer) to each sample. Votex samples. 
The amount of sample to prepare depends on the size of the well for the gel. 
 
 Denatured samples by putting in Fisher Dry Bath at 100ºC for 5 minutes. 
 
 
 Placed gel in electrophoresis container with 1X running buffer. Ran at 225V. (4–
20% Criterion™ TGX™ Gel, 12+2 well, 45 µl) 
 
 Prepared nitrocellulose membrane and filter paper stacks. Moistened 
Nitrocellulose and filter paper in 1X transfer buffer for 30 minutes. 
 
 
 Set up Trans Blot – Midi gel (2.5A, 25V, 7 min) 
 
 Placed in tray of water for 10 minutes 
 
 
 Placed membrane in appropriately sized cassette and added blocking buffer until 
the membrane is covered. Closed cassette and put on shaker for 1 hour. 
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 Prepared 10 mL primary antibody solution in blocking buffer to desired 
concentration.    Placed on shaker for 1 hour using surface transfer mechanisms. 
 
 
 Washed with blocking buffer (or wash buffer) 3 times for 5 min each on shaker at 
room temperature. 
 
 Prepared 10 mL secondary antibody solution in blocking buffer. These antibodies 
are sensitive to light so wrapped the cassette in in foil while incubating for 1 hour. 
 
 
 Washed with blocking buffer 6 times for 5 min each on shaker at room 
temperature. 
 
 Mixed ECL reagents - 6 mL of one and 6 mL of the other. Did not mix until right 
before use. Added to the membrane – 5 minutes. 
 
 












RESULTS AND DISCUSSION 
 
 
1. STANDARD CURVES  
 
 
Figure 11: Typical absorbance plot for BSA using a spectrophotometer procedure – 




































Figure 12: Typical absorbance plot for BSA using a microplate procedure – 
Bradford Assay at 595 nm 
 
Determinations are made with a high level of confidence (r2 = 0.98). Determinations in 
the lower portion of the curve offer the greatest degree of accuracy with a polynomial fit 
due to the greater change in signal verses change in protein concentration. 
 
2.  LYSIS  
 
Different approaches to extraction using homogenization (H) and/or sonication(S) with 
RIPA and/or Urea buffers were attempted on mice brain samples and total protein 
concentration was calculated using the Bradford Assay. 
 





























































Sample Buffer Conc. 
(µg/mL) 
    
1. A RIPA 47 
2. B Urea 699 
3. C RIPA 149 
4. D Urea 647 
5. E RIPA 46 
6. F Urea 636 
Sr. No Sample Buffer Conc. (µg/mL) 
    
1. G RIPA 26 
2. H Urea 689 
3. I RIPA 42 
4. J Urea 615 
5. K RIPA 41 














Table 6: Final Optimization of extraction protocol 
 
3.  PROTEIN CONCENTRATIONS FROM DIFFERENT EXTRACTION FRACTIONS  

















     
1 11 81 24 73 
2 18 99 31 95 
3 21 37 19 28 
4 60 70 13 61 
5 42 69 33 55 
6 70 98 53 60 
7 29 71 40 63 
8 41 73 67 59 
 
Table 7: Protein concentrations from different extraction regions of Normal 
CERAD-B category patients. Highest concentration was found in samples from 
Extracellular regions and lowest varied between Cellular and Insoluble fractions. 
Sample Buffer Method Amount (mg) Total Protein (µg/mL) 
     
1 RIPA S 50 1301.857 
2 RIPA H 50 426.159 
3 RIPA S+H 50 1321.339 
4 RIPA S 25 1294.484 
5 RIPA H 25 332.493 
6 RIPA S+H 25 1273.665 
7 Urea S 50 992.284 
8 Urea H 50 992.207 
9 Urea S+H 50 1085.339 
10 Urea S 25 1021.736 
11 Urea H 25 958.286 


















     
1 43 145 53 38 
2 202 216 117 198 
3 185 189 242 188 
4 178 249 173 174 
5 185 249 119 150 
6 187 218 109 160 
7 110 220 56 108 
 
Table 8: Protein concentrations from different extraction regions of MCI category 
patients. Highest concentrations were found in Extracellular fractions. Lowest 

















     
1 149  161 50 143 
2 65 173 32 50 
3 53 98 51 73 
4 91 101 74 85 
5 117 147 114 136 
6 99 153 87 147 
7 106 160 39 56 
8 111 181 68 128 
9 97 114 75 101 
 
Table 9: Total protein concentrations from different extraction regions of Demented 
CERAD-B category patients. Highest concentrations were found in Extracellular 





















     
1 31 51 7 42 
2 26 47 6 41 
3 58  79 48 61 
4 73 87 34 59 
5 76 91 56 82 
6 88 94 46 71 
7 63 78 32 72 
8 42 53 37 49 
9 66 81 43 58 
 
Table 10: Protein concentrations from different extraction regions of Demented 
CERAD-C category patients. Highest concentrations were found in Extracellular 













NORMAL 18 99 31 
NORMAL 70 98 53 
MCI 178 249 173 
MCI 110 220 56 
AD 76 91 56 
AD 88 94 46 
 
Table 11: Summary of Protein Concentrations: MCI patients have larger total 
















































1 TOMM40 1:5000  
 





1:3333 3 µL 1:1000 10 µL 10 
4 COX IV 1:1000 
 
1:1000 10 µL 1:5000 2 µL 10  
 













5.  WESTERN BLOTS  
 
























Figure 13: Western Blot Analysis of mice brain samples using RIPA (R) and urea 
(U) buffer with TOMM40 antibody of primary and secondary concentration of 
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Figure 14: Western Blot Analysis of mice brain samples using RIPA (R) and urea 
(U) buffer with synaptophysin antibody of primary concentration= 1:10000 and 
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Figure 15: Western Blot Analysis of mice brain samples using RIPA (R) and urea 
(U) buffer with COX-IV antibody of primary concentration= 1:1000 and secondary 

















U     U     U    U    U    U    R   R     R    R     R     R  
 38 











Figure 16: Western Blot Analysis of mice brain samples from patient categories: 
Normal (N), MCI (M), AD from CERAD-B and CERAD-C using RIPA buffer with 
TOMM40 antibody of primary and secondary concentration of 1:5000. TOMM40 













































Figure 17: Western Blot Analysis of mice brain samples from patient categories: 
Normal (N), MCI (M), AD from CERAD-B (1) and CERAD-C (2) using RIPA 
buffer with synaptophysin antibody of primary concentration = 1:10000 and 
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Figure 18: Western Blot Analysis of mice brain samples from patient categories: 
Normal (N), MCI (M), AD from CERAD-B (1) and CERAD-C (2) using RIPA 
buffer with COX-IV antibody of primary concentration = 1:1000 and secondary 
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c. Westerns with full length proteins  
 
 



























Figure 19: Western Blot Analysis of mice brain samples from patient categories: 
Normal (N), MCI (M), AD from CERAD-B (1) and full length synaptophysin 
peptide (P) using RIPA buffer with synaptophysin antibody of primary 
concentration = 1:10000 and secondary concentration = 1:1000. Synaptophysin has a 














































Figure 20: Western Blot Analysis of mice brain samples from patient categories: 
Normal (N), MCI (M), AD from CERAD-B (1) and using RIPA buffer with COX-IV 
antibody of primary concentration = 1:1000 and secondary concentration = 1:2000.  





Comparison of protein concentration using Mass spectrometry across 3 patient groups 
will give us a better understanding of the roles of TOMM40, COX-1V, synaptophysin 
and PSD95 in AD, correlating temporal relationship of synaptic dysfunction to onset of 
cognitive dysfunction in AD patients. 
N       N       M      M     1       1       P        P      P 
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d. Human brain tissue powdered using liquid nitrogen 
 
(i)  Protein Concentrations from Normal, MCI, Demented CERAD-B and CERAD-C 







   
1 NORMAL 142.26 
2 NORMAL 60.268 
3 NORMAL 32.599 
4 NORMAL 184.82 
5 NORMAL 750.81 
6 NORMAL 1736.36 
7 NORMAL 1906.25 
   
8 MCI 1433.61 
9 MCI 699.4 
10 MCI 137.61 
11 MCI 75.14 
12 MCI 397.53 
13 MCI 2066.45 
14 MCI 1698.29 
   
15 DEM. CERAD B 1463.55 
16 DEM. CERAD B 1894.35 
17 DEM. CERAD B 1461 
18 DEM. CERAD B 347 
19 DEM. CERAD B 41 
   
20 DEM. CERAD C 377.78 
21 DEM. CERAD C 1691.21 
22 DEM. CERAD C 1969.55 
23 DEM. CERAD C 1747.26 
24 DEM. CERAD C 1733.04 
25 DEM. CERAD C 1312.04 
26 DEM. CERAD C 310.82 
 
Table 13: Protein Concentrations from Normal, MCI, Demented CERAD-B and 






























Figure 21: Western Blot Analysis of mice brain samples powdered using liquid 
nitrogen from patient categories: Normal (N), MCI (M), AD from CERAD-B (1) 
and CERAD-C (2) using RIPA buffer with TOMM40 antibody of primary and 
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While optimizing the protocol for best extraction of proteins from brain samples, it was 
clear that using a mortar and pestle prior to subjecting samples to homogenization yielded 
best results. Without initial grinding, the sonication and homogenization process did not 
take place smoothly and caused the equipment to only partially homogenize tissue. Using 
lab prepared Urea buffer with protease inhibitors and absorption at 750nm seemed to 
always yield similar total protein concentrations which was abnormal. This was rectified 
when no protease inhibitors were used.  Urea buffer in Westerns showed high 
background. Proteins were precisely quantified against recombinant truncated protein 
standards. It was eventually seen that a combination of sonication and homogenization 
using the RIPA buffer yielded maximum total protein content using the Bradford assay at 
absorption 595nm. It was interesting to note that in all category of patients (Normal, 
MCI, CERAD-B and CERAD-C), highest protein concentrations were seen in 
extracellular fractions (E). In Normal patients, lowest concentrations varied between 
Cellular and Insoluble fractions. In MCI patients, least protein concentrations were seen 
predominantly in the insoluble fractions. The same result was observed in CERAD-B and 
CERAD-C patients as well. It was seen that MCI patients have the largest total  protein 
concentrations among all patient groups. TOMM40, Synaptophysin and COX-IV were 
detected using preliminary Western Blots. PSD-95 was not detected in mice brain or 
human brain samples.  Synaptophysin protein expression was markedly reduced in MCI 
patients which correlates correctly with the role of synaptophysin. Controls with full 
length proteins were used to make sure we are detecting the right protein in given patient 
categories and samples. Synaptophysin showed a marked increase in all normal patients 
which correctly correlates with its synaptic function. Cytochrome c oxidase (COX-IV) 
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showed increased concentrations in patients with Alzheimer’s disease (CERAD-B and 
CERAD-C). TOMM40 showed a uniform concentration across all patient groups which 
negates its hypothesized function and role in Alzheimer’s disease. Comparison of protein 
concentration using Mass spectrometry across three patient groups will give us a better 
understanding of the roles of TOMM40, COX-1V, synaptophysin and PSD95 in AD, 
correlating temporal relationship of synaptic dysfunction to onset of cognitive 
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Medicine, Baltimore, Maryland, USA, February 2015 
 Alzheimer’s Disease Research Summit 2015, National Institutes of Health, 
Bethesda, Maryland, USA, February 2015 
 National Conference on “Recent advances, career prospects and Entrepreneurial 
Opportunities in Bioengineering and Biotechnology”, March 2014, Sir M 
Visvesvaraya Institute of Technology, India. 
  Presented a poster titled, “Computational Examination to appreciate intrinsic   
conformational flexibility of Heat Shock Protein 90 implicated in Alzheimer's 
disease”. 
 Have given over 30 presentations on topics such as Intrinsically disordered 
proteins, Drug Delivery Systems, Isozymes, Bioprocess Equipment Design etc. 
during the course of my Undergraduate career in Department of Biotechnology 
 Indian Institute of Science International Conference on Biomolecular forms and 
functions, January 2013, Indian Institute of Science, India. 
 National Conference on Biopharmaceuticals and Healthcare, November 2011, Sir 
M Visvesvaraya Institute of Technology, India. 
a. Presented a poster titled, “Drug development for neurodegenerative 
diseases by Pharmaceutical Companies in India” 
Volunteer Experience  
 Growing Minds Initiative, Board of Directors, Baltimore       Mar.2015 – Present                    
 A Non-Governmental Organization that works on educational needs for Orphaned 
and Vulnerable Children (OVC) in Tanzania. 
 Medical Volunteer Experience 
 JHU Visionaries – shadowing medical professionals, conducting patient 
interviews at the Wilmer Eye Institute 
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 EEG and Neuroprosthetics Section of the Functional Performance and Device Use 
Lab at the Food and Drug Administration (FDA) – selected but could not take it 
up 
 Submitted a proposal for the GE Edison Challenge for healthcare innovation in 
India 
 Online courses: Fixing Healthcare Delivery, Neurons and Networks, Operations 
Management, Proteins: Biology’s Workforce, Introduction to Computer Science 
                         




1. FDA – Introduction to FDA Human Drug Review and Approval Basics 
2. FDA – Centre for Drug Evaluation and Research, Advisory Committee Process 
Review 
3. FDA – Overview of Generic Drugs 
4. FDA – Overview of Drug Safety 
5. FDA – Role of Office of New Drugs 
6. FDA – World of Compliance, Overview 
7. Johns Hopkins Medicine – Intermediate Privacy Course for Health Care Providers 
( Clinicians and Non Clinicians) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
